{"product_id":"biolegend-502510","title":"Biolegend, 502510, PE anti-human IFN-γ Antibody, 50μg","description":"\u003cp\u003eInterferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Partially purified, native human IFN-γ\u003cbr\u003e\nFormulation: µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: µg sizes: 0.2 mg\/mLtest sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For test size, the suggested use of this reagent for immunofluorescent staining is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For µg size, the suggested use of this reagent for immunofluorescent staining is 0.05 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402\/502404) or purified MD-1 antibody (Cat. No. 507502\/507513) as the capture antibody.Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations.Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)\u003cbr\u003e\nProduct Citations: Ishii H, et al. 2016. Sci Rep. 6:30153. PubMed Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed Kim MY, et al. 2021. JCI Insight. 6:. PubMed Cuadrado E, et al. 2018. Immunity. 48:1046. PubMed Wang F, et al. 2018. Oncogenesis. 7:41. PubMed Hermans L, et al. 2021. Front Immunol. 634402:12. PubMed Chen L, et al. 2018. Immunology. 155:123. PubMed Tang W, et al. 2019. Oncoimmunology. 8:e1593807. PubMed Tian X, et al. 2021. Annals of Translational Medicine. 9(9):781. PubMed Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed Qiu XM, et al. 2020. Reproduction. 251:159. PubMed Longhi M, et al. 2014. PLoS One. 9:87956. PubMed Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed Chandran P, et al. 2014. J Leukoc Biol. 96:633. PubMed Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed Szentkereszty M, et al. 2020. Pathol Oncol Res. 26:1117. PubMed Yan Y, et al. 2018. JCI Insight. 3. PubMed Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed Ishii H, et al. 2022. Cell Rep Med. 3:100520. PubMed Hombrink P, et al. 2016. Nat Immunol. 17:1467-1478. PubMed Almeida VG, et al. 2017. Braz J Med Biol Res. 50:e5163. PubMed Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed Teni Nurlatifah HR, et al. 2021. Med Arch. 75:335. PubMed Zhang W, et al. 2022. J Transl Med. 20:558. PubMed Guimarães F, et al. 2017. J Pediatr (Rio J). 10.1016\/j.jped.2017.08.005. PubMed Roudko V, et al. 2020. Cell. 183(6):1634-1649.e17. PubMed Katsuyama E, et al. 2020. Cell Reports. 30(1):112-123.e4.. PubMed Hr TN, et al. 2021. Allergol Immunopathol (Madr). 49:193. PubMed Gussarow D, et al. 2021. Front Med (Lausanne). 8:770381. PubMed Lu H, et al. 2020. Oncoimmunology. 9:1748991. PubMed Xian S, et al. 2021. EMBO Rep. 22:e52509. PubMed Zanetti S, et al. 2016. J Biol Chem. 291: 16541 - 16552. PubMed Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed Faissner S, et al. 2022. Front Immunol. 13:980526. PubMed Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed\u003cbr\u003e\nRRID: AB_315233 (BioLegend Cat. No. 502508) AB_315235 (BioLegend Cat. No. 502510) AB_315234 (BioLegend Cat. No. 502509)\u003cbr\u003e\nStructure: Cytokine; dimer; 20-25 kD (Mammalian)\u003cbr\u003e\nBioactivity: Antiviral\/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC\u003cbr\u003e\nCell Sources: CD8+ and CD4+ T cells, NK cells\u003cbr\u003e\nCell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.\u003cbr\u003e\nRegulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2\u003cbr\u003e\nGene ID: 3458\u003cbr\u003e\nUniProt: View information about IFN-gamma on UniProt.org\u003cbr\u003e\nClone: 4S.B3\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862419689641,"sku":"502510","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-502510","provider":"Iright","version":"1.0","type":"link"}